ITRARAN 200 Capsules contain Itraconazole 200 mg, a potent antifungal agent specially formulated for the treatment of a wide range of systemic and deep fungal infections. This pharmaceutical-grade medication is highly effective against dermatophytoses (skin fungal infections), onychomycosis (fungal nail infections), coccidioidomycosis (mild to moderate cases), chromoblastomycosis (chronic cutaneous fungal infections caused by pigmented fungi), blastomycosis, and histoplasmosis. Its unique formulation requires an acidic gastric environment to ensure optimal absorption, thus it is recommended to be taken with food. Itraconazole targets specific fungal pathogens such as Blastomyces dermatitidis, Histoplasma capsulatum, and Trichophyton rubrum making it a reliable alternative to fluconazole for treating fungal infections both acute and chronic. Approved by the FDA, ITRARAN 200 Capsules are an essential treatment for healthcare providers managing complex fungal conditions, offering effective systemic therapy with high patient compliance.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Itraconazole 200 mg |
| Formulation | Capsules |
| Therapeutic Use | Systemic and Deep Fungal Infections |
| Indications | Blastomycosis, Histoplasmosis, Onychomycosis, Dermatophytoses, Chromoblastomycosis, Coccidioidomycosis |
| Absorption Requirement | Requires acidic gastric environment, take with food |
| FDA Approved Treatments | Acute and chronic blastomycosis, mild to moderate histoplasmosis, onychomycosis with nail matrix involvement |
| Alternative To | Fluconazole |
| Pathogens Targeted | Blastomyces dermatitidis, Histoplasma capsulatum, Trichophyton rubrum, Fonsecaea |
| Dosage Form | Oral capsules |
| Attributes | Description |
|---|---|
| Dosage Strength | 200 mg per capsule |
| Packaging | 200 capsules per container |
| Storage Conditions | Store below 30°C, protect from moisture and light |
| Administration Route | Oral |
| Pharmacological Class | Antifungal agent |
| Mechanism of Action | Inhibits fungal cytochrome P450 enzyme resulting in impaired ergosterol synthesis |
| Absorption | Enhanced by acidic gastric environment |
| Common Dosage Regimen | Administered with food to increase bioavailability |
| Contraindications | Patients with ventricular dysfunction or history of heart failure |
| Drug Interactions | Avoid co-administration with CYP3A4 substrates metabolized drugs without medical supervision |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
ITRARAN 200 Capsules require an acidic gastric environment for effective absorption; hence, it should be taken with food to enhance bioavailability.
Yes, according to FDA guidelines, ITRARAN 200 Capsules are approved to treat both pulmonary and extrapulmonary (non-meningeal) forms of blastomycosis.
Yes, treatment with ITRARAN 200 Capsules for onychomycosis is approved only when the nail matrix is involved and diagnosis is confirmed by laboratory tests such as KOH prep or fungal culture.
ITRARAN 200 Capsules serve as an effective alternative to fluconazole, particularly in treating systemic and deep fungal infections due to their broad spectrum and potent antifungal activity.
Yes, ITRARAN 200 Capsules have proven efficacy in treating chromoblastomycosis, a chronic cutaneous fungal infection caused by pigmented fungi such as Fonsecaea species.
Brand: itraran 200
Country Of Origin: India
ITRACONAZOLE 200 FOR Systemic and deep fungal infections, Dermatophytoses (skin fungal infections),Onychomycosis (fungal nail infection),Coccidioidomycosis (Mild to Moderate Cases)Alternative to fluconazole,.Chromoblastomycosis
Chronic cutaneous fungal infection caused by pigmented fungi (e.g., Fonsecaea)
Capsules require acidic gastric environment for absorption.
Take with food.
Blastomycosis
Causative organism: Blastomyces dermatitidis
Histoplasmosis
Causative organism: Histoplasma capsulatum
According to FDA labeling, Itraconazole capsules are approved for the treatment of the following systemic fungal infections:
1. Blastomycosis
Causative organism: Blastomyces dermatitidis
Types: Pulmonary and extrapulmonary (non-meningeal)
✅ Itraconazole is approved for treatment of both acute and chronic forms.
2. Histoplasmosis
Causative organism: Histoplasma capsulatum
Types:
Chronic cavitary pulmonary histoplasmosis
Disseminated (non-meningeal) histoplasmosis
✅ Itraconazole is used for mild to moderate disease, and for long-term oral therapy.
3. Onychomycosis of the Toenail (with or without fingernail involvement)
Causative organism: Dermatophytes, mainly Trichophyton rubrum
✅ Approved for treatment of onychomycosis only when:
Nail matrix is involved
Diagnosis confirmed by lab testing (e.g., KOH prep, culture)
Inclusive of all taxes
You Save: 0
Noida , India
Contractor, Brand Owner, Distributor, Exporter, Importer, Wholesaler
GST- 09aaocr0046g1zb
